Application of inosine in preparation of medicines for preventing and treating tuberculosis

A tuberculosis and drug technology, applied to the application field of inosine in the preparation of drugs for preventing and treating tuberculosis, can solve the problems of down-regulation, unreported application, unclear action and mechanism, etc., to promote clearance, inhibit in vivo survival, inhibit Effects of exacerbation of tuberculous granulomas

Pending Publication Date: 2021-12-21
SHANGHAI PULMONARY HOSPITAL
2 Cites 0 Cited by

AI-Extracted Technical Summary

Problems solved by technology

In the early stage, through the comparative metabolomics analysis of the lung and peripheral blood of Mtb-infected granuloma mice, we found that the content of inosine in the lung granuloma and peripheral blood of mice was significantly down-regulated, suggesting that inosine may be inv...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Method used

2. lung histopathology detection: collect lung under aseptic condition, get part lung tissue and fix with 4% paraformaldehyde, dehydration, wax dipping, embedding, section, H&E and acid-fast staining, microscope observation lung Histopatholog...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Abstract

The invention provides an application of inosine in preparation of medicines for preventing and treating tuberculosis. According to the invention, the inosine is proven to significantly reduce microbial load in the lung of an mycobacterium tuberculosis (Mtb) infected mouse, alleviate pathological changes, inhibit deterioration of tuberculous granuloma, and significantly promote expression of IL-1beta and IL-6 genes so as to promote elimination of Mtb by macrophages, thereby inhibiting in-vivo survival of Mtb. Therefore, inosine is expected to serve as a new effective metabolic molecule for preparing medicines for preventing and treating tuberculosis, and provides a new strategy for treating tuberculosis.

Application Domain

Technology Topic

InosineMycobacterium +8

Image

  • Application of inosine in preparation of medicines for preventing and treating tuberculosis
  • Application of inosine in preparation of medicines for preventing and treating tuberculosis
  • Application of inosine in preparation of medicines for preventing and treating tuberculosis

Examples

  • Experimental program(5)

Example Embodiment

[0031] Example 1
[0032] In this example, C57BL/6 mice were used to infect the H37Rv model to analyze the effect of inosine on tuberculosis. The specific experimental steps and results are as follows:
[0033] Six to eight-week-old female C57BL/6 mice, 6 in each group, were infected with H37Rv strain by intranasal drip, about 200 CFU/mouse. After 3 weeks of infection, the control group added 1% DMSO to the drinking water, and the inosine group added 1% inosine to the drinking water, and the mice were sacrificed after 4 weeks of administration. The effect of inosine on tuberculosis infection in mice was analyzed by detecting the following indicators:
[0034] ① Bacterial load in the lungs: Collect lungs under sterile conditions, add PBS homogenate, inoculate on 7H10 agar medium after 10-fold dilution, and incubate at 37°C for 4 weeks, observe the growth of H37Rv, calculate the bacterial load in the lungs, and find that infection After H37Rv mice drank inosine, the bacterial load in the lungs was significantly reduced ( figure 1 ).
[0035] ②Pulmonary histopathological examination: collect the lungs under sterile conditions, take part of the lung tissue and fix it with 4% paraformaldehyde, dehydrate, soak in wax, embed, section, H&E and acid-fast staining, and observe the lung histopathology under a microscope Compared with the control group, the pathological changes in the lungs of the infected mice drinking inosine were significantly reduced, and the infiltration of immune cells and lung tissue damage were also significantly reduced ( figure 2 ).
[0036] The above results indicated that inosine can significantly improve the host's ability to resist Mtb.

Example Embodiment

[0037] Example 2
[0038] In this example, the zebrafish infection model is used to analyze the effect of inosine on mycobacterial diseases, especially granuloma. The specific experimental process and results are as follows:
[0039] Wild-type zebrafish (strain AB) was purchased from the China Zebrafish Resource Center, reared in a recirculation culture system, and transferred to a toxicology system for mycobacterium marinum infection experiments, while ensuring the standard conditions for zebrafish rearing and infection (water temperature about 28 ℃, pH about 7.4, conductivity about 1,500μS). After adult zebrafish were anesthetized with 0.1% tricaine, they were infected with Mycobacterium marinum by intraperitoneal injection. The amount of infected bacteria was about 200 CFU. One week later, the control group was orally administered DMSO, and the inosine group was orally administered 0.01 mg inosine. They were sacrificed 1 week after administration, and the effect of inosine on the development of granuloma in adult zebrafish infected with Mycobacterium marinum was analyzed by the following indicators:
[0040](1) Bacteria load: After infection and administration, the zebrafish were terminally anesthetized in 0.5% tricaine, homogenized in PBS, diluted 10 times, inoculated on 7H10 agar medium, and cultured at 37°C for 1-2 weeks , observed the growth of Mycobacterium marinum in different groups, and calculated the number of live bacteria CFU. It was found that the adult fish in the oral inosine group had a lower bacterial load, and it was dose-dependent ( image 3 ).
[0041] (2) Histopathological examination: After infection and administration, the zebrafish were terminally anesthetized in 0.5% tricaine, and the whole fish was fixed in 4% neutral buffered paraformaldehyde solution for 72 hours, decalcified and soaked in wax , embedding, sectioning, H&E and acid-fast staining, the whole fish was observed under a microscope, mainly the pathological changes of granuloma in kidney and liver tissue. Figure 4 ).
[0042] The above results show that inosine can significantly improve the host's ability to resist mycobacteria, and reduce the formation and deterioration of granulomas.

Example Embodiment

[0043] Example 3
[0044] In this embodiment, the effect of inosine on the survival of intracellular Mtb in macrophages was analyzed using the in vitro infection model of macrophages. The specific experimental process and results are as follows:
[0045] Take the primary peritoneal macrophages of wild-type mice, and culture them with complete 1640 medium (containing 10% FBS + 1% penicillin-streptomycin) at 37°C for 4 hours. Glycosides were used to make the final concentration of 50 μM, and H37Rv was infected 12 hours later, MOI=5. After 3 hours of infection, the supernatant was removed, the cells were washed three times with PBS to remove extracellular bacteria, and the number of bacteria entering the cells was counted by CFU. After another part of the cells were washed, 1640 medium containing DMSO or 50 μM inosine was added to continue culturing for 24 hours, and the survival of intracellular bacteria was detected by CFU. It was found that inosine significantly promoted the intracellular clearance of Mtb by macrophages, see Figure 5.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Similar technology patents

Treating infectious diseases using ice inhibitors

InactiveUS20050233974A1Reduce clinical scoreReduce bacterial loadAntibacterial agentsBiocideIrritationCompound (substance)
Owner:VERTEX PHARMA INC

Application of inosine in preparing medicine for preventing decompression sickness caused by fast buoyancy ascent escape

ActiveCN105412139AReduces lung damage and inflammationAlleviate pathological changesOrganic active ingredientsPharmaceutical delivery mechanismInosineEdema
Owner:NAVY MEDICINE RES INST OF PLA

Application of arctigenin in preparation of medicine for treating chronic atrophic gastritis

PendingCN108721274AAlleviate pathological changesReduce atrophyOrganic active ingredientsDigestive systemDrugGastric mucosa
Owner:LUNAN PHARMA GROUP CORPORATION

Classification and recommendation of technical efficacy words

  • Reduce bacterial load
  • Alleviate pathological changes

Treating infectious diseases using ice inhibitors

InactiveUS20050233974A1Reduce clinical scoreReduce bacterial loadAntibacterial agentsBiocideIrritationCompound (substance)
Owner:VERTEX PHARMA INC

Application of inosine in preparing medicine for preventing decompression sickness caused by fast buoyancy ascent escape

ActiveCN105412139AReduces lung damage and inflammationAlleviate pathological changesOrganic active ingredientsPharmaceutical delivery mechanismInosineEdema
Owner:NAVY MEDICINE RES INST OF PLA

Application of arctigenin in preparation of medicine for treating chronic atrophic gastritis

PendingCN108721274AAlleviate pathological changesReduce atrophyOrganic active ingredientsDigestive systemDrugGastric mucosa
Owner:LUNAN PHARMA GROUP CORPORATION

People also interested in

Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products